Organization
Laboratory of Pathology, NCI, NIH, Bethesda, MD
5 abstracts
Abstract
Effect of rituximab on remissions without minimal residual disease and immunogenicity in patients with relapsed/refractory hairy cell leukemia receiving moxetumomab pasudotox.Org: Laboratory of Molecular Biology, NCI, NIH, Bethesda, MD, Laboratory of Pathology, NCI, NIH, Bethesda, MD, Office of Research Nursing, NCI, NIH, Bethesda, MD, Hematology Service, DLM, NIH, Bethesda, MD,
Abstract
Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome.Org: Pangea Biomed, National Cancer Institute, Vilnius, Lithuania, Cancer Data Science Laboratory (CDSL), National Institutes of Health All of Us Research Program, Women’s Malignancies Branch,
Abstract
Phase II trial evaluating nivolumab in patients with recurrent IDH-mutant gliomas with and without hypermutation phenotype.Org: Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Bethesda, MD,
Abstract
A phase II study of tremelimumab, durvalumab, and bevacizumab in advanced biliary tract cancers.Org: Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Laboratory of Pathology, NCI, NIH, Bethesda, MD,
Abstract
ANTIARTHRITIC EFFECT OF IMMUNOMODULATOR DERINAT ALONE AND IN COMBINATION WITH METHOTREXATE ON ADJUVANT ARTHRITIS IN RATSOrg: Laboratory of Pathology, NCI, NIH, Bethesda, MD, Laboratory of Immunology, College of Pharmacy, Seoul National University and Cellid, Inc., Institute of Experimental and Clinical Medicine, Vilnius, Lithuania,